Editas Medicine and Genevant Sciences Join Forces
CAMBRIDGE, Mass. and VANCOUVER, British Columbia, and BASEL, Switzerland – Editas Medicine, Inc. (NASDAQ: EDIT), a leading force in gene editing, has announced an exciting new collaboration with Genevant Sciences, a renowned expert in nucleic acid delivery systems. Through this partnership, the two companies will merge Editas’s pioneering CRISPR Cas12a genome editing technology with Genevant’s advanced lipid nanoparticle (LNP) technology. This collaboration aims to develop innovative in vivo gene editing therapeutics targeting undisclosed biomarkers related to Editas's upregulation strategy.
Commitment to Innovation in Gene Editing
Linda C. Burkly, Ph.D., the Chief Scientific Officer of Editas Medicine, expressed enthusiasm about this partnership. She highlighted that Editas is driven by the ambition of becoming a leader in the field of programmable gene editing medicine. Burkly noted the ongoing progress toward clinical applications as the company works on a robust pipeline of treatments.
Burkly pointed out that the collaboration with Genevant was a natural choice. Editas recognized Genevant’s strong position in the LNP delivery landscape as it explored options for delivering its CRISPR technology effectively. Excitement about the collaboration was evident as the partnership promises the development of new therapeutic modalities that hold the potential to transform treatment approaches.
Genevant Sciences: A Leader in Nucleic Acid Delivery
Genevant Sciences, with its extensive experience in delivering nucleic acids, looks to combine its expertise with Editas Medicine. The Chief Scientific Officer of Genevant, James Heyes, stated that they are excited to collaborate with Editas to create potentially groundbreaking gene editing therapies. He emphasized the importance of LNPs in delivering gene editing constructs and expressed optimism regarding the unique strengths that both companies bring to the table.
Collaboration Details and Financial Outlook
The terms of this collaboration involve Genevant granting Editas a nonexclusive worldwide license to utilize specific Genevant LNP technology for developing mRNA-CRISPR Cas12a-LNP products. This agreement represents a significant financial opportunity for Genevant, which stands to gain up to $238 million in upfront funding and milestone payments, along with tiered royalties pending the success of any resulting product sales.
About Editas Medicine
Editas Medicine is dedicated to advancing gene editing technologies aimed at providing transformative therapies for serious diseases globally. The company is focused on harnessing the CRISPR/Cas12a and CRISPR/Cas9 systems, with a vision to create a comprehensive pipeline of genomic medicines. As the exclusive licensee of key CRISPR patents, Editas is well-positioned to lead in the evolution of genomic medicine.
About Genevant Sciences
Genevant Sciences stands at the forefront of nucleic acid delivery, boasting a suite of platforms and a strong patent portfolio in lipid nanoparticles. With decades of specialized experience, Genevant has successfully driven industry-leading advancements in LNP technology, applicable to a diverse range of RNA-based therapies, including vaccines and gene editing.
Frequently Asked Questions
What is the primary aim of the collaboration between Editas and Genevant?
The collaboration focuses on developing in vivo gene editing therapies using Editas's CRISPR technology and Genevant's lipid nanoparticle delivery systems.
What technology is Editas leveraging in this partnership?
Editas is utilizing its CRISPR Cas12a genome editing systems in conjunction with Genevant's lipid nanoparticle technology.
What potential financial benefits does Genevant stand to gain?
Genevant could receive up to $238 million in milestone payments and tiered royalties based on future product sales resulting from this collaboration.
How does Editas Medicine plan to innovate in gene therapy?
Editas aims to develop a robust pipeline of genomic medicines targeted at serious diseases by utilizing cutting-edge gene editing technologies.
What experience does Genevant bring to the collaboration?
Genevant brings over 20 years of experience in nucleic acid delivery and a well-established lipid nanoparticle platform, critical for effective gene editing.
